- Aditxt ( NASDAQ: ADTX ) stock rose ~7% on Friday after the company said its program Adimune started the GMP manufacturing of immunotherapy drug candidate ADI-100 for its first-in-human trials in H2 2023.
- Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied, the company added.
- Aditxt noted that its Adimunes nucleic acid-based technology called Apoptotic DNA Immunotherapy (ADI) restores/induces immune tolerance in an antigen-specific way and potentially has efficacy benefit without immune suppression.
For further details see:
Aditxt stock rises as manufacturing of immunotherapy begins for planned psoriasis trial